Genetic Mutations and Family History
38 Articles
New Drug for BRCA Carriers with Advanced Cancer
A phase I clinical trial is testing the effectiveness of a platinum-based drug for BRCA carriers with pancreatic, breast, and other cancers.
Most Cancer Mutations Are Random DNA Mistakes
In a large study, Dr. Bert Vogelstein of Johns Hopkins found that a majority of cancers, including pancreatic cancer, are caused by random mutations of DNA.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Focusing on a Drug that Treats Specific Tumor Mutations
A clinical trial tests a signal-inhibiting drug for lung cancers with specific genetic mutations on gastrointestinal cancers with the same tumor mutations.
Treating BRCA-Negative Pancreatic Cancer Patients with a Family Cancer History Similar to BRCA Carriers
A clinical trial looks at the effectiveness of a PARP inhibitor in BRCA-negative pancreatic cancer patients with a family history BRCA-type cancers.
BRCA’s Role in Pancreatic Cancer Investigated
The relationship between BRCA and pancreatic cancer, and how that affects treatment, is the focus of clinical trials looking at PARP inhibitors.
Pancreatic Cancer Tissue Helps Unlock the Disease’s Secrets
Dr. Christine Iacobuzio-Donahue at Memorial Sloan Kettering is using techniques from evolutionary biology to learn how pancreatic cancer grows.
Maintenance Chemotherapy Trial for Pancreatic Cancer Patients with the BRCA Mutation
A clinical trial for patients with BRCA mutations uses a PARP inhibitor as part of the maintenance chemotherapy experimental treatment.